Immune Reconstitution Inflammatory Syndrome in the Intensive Care Unit: A Contemporary Review for Critical Care Practitioners

Dr Neeraj Manikath ,claude.ai

Abstract

Background: Immune Reconstitution Inflammatory Syndrome (IRIS) represents a paradoxical inflammatory response following immune system recovery in critically ill patients. While classically described in HIV patients initiating antiretroviral therapy, IRIS has emerged as a significant clinical entity in ICU settings, particularly following sepsis recovery, steroid withdrawal, and immunosuppression cessation.

Objective: To provide a comprehensive review of IRIS in ICU patients, focusing on pathophysiology, clinical manifestations, diagnosis, and management strategies for critical care practitioners.

Methods: Narrative review of current literature with emphasis on ICU-relevant IRIS presentations and evidence-based management approaches.

Results: IRIS manifests in two primary forms in ICU patients: unmasking IRIS (revealing previously subclinical infections) and paradoxical IRIS (worsening of known infections despite appropriate therapy). Common triggers include steroid withdrawal, sepsis recovery, and discontinuation of immunosuppressive agents. Management requires a delicate balance between anti-inflammatory therapy and infection control.

Conclusions: Recognition and appropriate management of IRIS in ICU patients requires high clinical suspicion, systematic diagnostic approach, and individualized treatment strategies. Early identification and prompt intervention can significantly improve patient outcomes.

Keywords: Immune reconstitution inflammatory syndrome, IRIS, critical care, sepsis, immunosuppression, steroid withdrawal

Introduction

Immune Reconstitution Inflammatory Syndrome (IRIS) represents one of the most challenging paradoxes in critical care medicine. First described in HIV patients initiating highly active antiretroviral therapy (HAART), IRIS has evolved beyond its original context to become a significant concern in intensive care units worldwide. The syndrome occurs when a recovering immune system mounts an exaggerated inflammatory response against previously controlled or subclinical pathogens, often resulting in clinical deterioration despite appropriate antimicrobial therapy.

In the ICU setting, IRIS presents unique diagnostic and therapeutic challenges. Unlike the well-characterized HIV-associated IRIS, ICU-related IRIS encompasses a broader spectrum of clinical scenarios, including post-sepsis immune recovery, steroid withdrawal syndromes, and cessation of immunosuppressive therapy in transplant recipients or patients with autoimmune conditions. The complexity is further amplified by the multifaceted nature of critical illness, where multiple organ dysfunction, polypharmacy, and evolving clinical conditions create a perfect storm for IRIS development.

Understanding IRIS in the ICU context is crucial for several reasons. First, the syndrome can mimic sepsis or treatment failure, potentially leading to inappropriate escalation of antimicrobial therapy or unnecessary procedural interventions. Second, the timing of IRIS onset often coincides with anticipated clinical improvement, making recognition challenging. Third, management requires a nuanced approach that balances inflammatory control with infection management, a delicate equilibrium that demands expertise in both infectious diseases and critical care medicine.

Pathophysiology

Immune System Dynamics in Critical Illness

The pathophysiology of IRIS in ICU patients begins with understanding the complex immune alterations that occur during critical illness. The initial phase of sepsis and severe illness is characterized by systemic inflammatory response syndrome (SIRS), featuring excessive pro-inflammatory cytokine release, complement activation, and widespread tissue damage. This hyperinflammatory state is typically followed by a compensatory anti-inflammatory response syndrome (CARS), characterized by immune suppression, T-cell anergy, and increased susceptibility to secondary infections.

During the recovery phase, immune reconstitution occurs as the balance between pro- and anti-inflammatory responses gradually normalizes. However, this process is not always smooth or predictable. In some patients, the recovering immune system encounters antigens from previously controlled pathogens, triggering an exaggerated inflammatory response that characterizes IRIS.

Molecular Mechanisms

The molecular basis of IRIS involves several key pathways. Central to the pathophysiology is the restoration of pathogen-specific T-cell responses, particularly CD4+ and CD8+ T-cell function. As these cells recover, they encounter antigens from opportunistic pathogens that were previously controlled by residual immune function or antimicrobial therapy. The subsequent immune activation leads to massive cytokine release, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and various chemokines.

The inflammatory cascade in IRIS is further amplified by the activation of antigen-presenting cells, particularly macrophages and dendritic cells. These cells, upon encountering pathogen-associated molecular patterns (PAMPs), release additional pro-inflammatory mediators and present antigens to T-cells, perpetuating the inflammatory cycle.

ICU-Specific Triggers

In the ICU setting, several specific triggers can precipitate IRIS:

Steroid Withdrawal: Corticosteroids suppress both innate and adaptive immunity. Rapid withdrawal or tapering can lead to immune rebound, particularly problematic in patients with underlying infections. The timing and rate of steroid reduction are critical factors in IRIS development.

Post-Sepsis Recovery: As patients recover from severe sepsis, immune function gradually returns. This recovery phase can unmask previously subclinical infections or trigger paradoxical worsening of treated infections.

Immunosuppressive Drug Cessation: Discontinuation of immunosuppressive agents in transplant recipients or patients with autoimmune conditions can trigger IRIS, particularly if occult infections are present.

Nutritional Recovery: Malnutrition profoundly affects immune function. Nutritional rehabilitation can restore immune competence and potentially trigger IRIS in patients with underlying infections.

Clinical Manifestations and Classification

Classification Systems

IRIS in ICU patients can be classified into two main categories, each with distinct clinical implications:

Unmasking IRIS: This form reveals previously subclinical or undiagnosed infections as immune function recovers. Common presentations include:

Fever and systemic inflammatory response in patients previously afebrile
New pulmonary infiltrates in patients with subclinical tuberculosis or fungal infections
Lymphadenopathy or hepatosplenomegaly
Neurological symptoms from unmasked CNS infections

Paradoxical IRIS: This form involves worsening of known infections despite appropriate antimicrobial therapy and occurs in patients with documented infections who experience clinical deterioration during immune recovery. Manifestations include:

Worsening respiratory symptoms in patients being treated for pneumonia
Increased inflammatory markers despite adequate antimicrobial coverage
New or worsening organ dysfunction
Progression of radiological findings

Temporal Patterns

The timing of IRIS onset in ICU patients follows predictable patterns:

Early IRIS (1-4 weeks): Typically occurs with rapid immune recovery or steroid withdrawal
Late IRIS (1-6 months): More common with gradual immune reconstitution
Delayed IRIS (>6 months): Rare but can occur with chronic immunosuppression withdrawal

Organ System Involvement

Pulmonary IRIS: The most common presentation in ICU patients, often manifesting as:

Acute respiratory distress with new infiltrates
Pleural effusions or pneumothorax
Acute respiratory failure requiring mechanical ventilation
Cavitary lesions or necrotizing pneumonia

Gastrointestinal IRIS: May present as:

Severe colitis or enteritis
Hepatitis with elevated transaminases
Pancreatitis
Gastrointestinal bleeding

Neurological IRIS: Can manifest as:

Altered mental status or confusion
Seizures or focal neurological deficits
Meningoencephalitis
Increased intracranial pressure

Cutaneous IRIS: Often presents as:

Erythematous rashes or nodules
Ulcerative lesions
Cellulitis or abscess formation

Diagnostic Approach

Clinical Criteria

Diagnosing IRIS in ICU patients requires a systematic approach combining clinical, laboratory, and microbiological findings. The following criteria should be considered:

Major Criteria:

Recent immune recovery (post-sepsis, steroid withdrawal, immunosuppression cessation)
Clinical deterioration despite appropriate antimicrobial therapy
Inflammatory response disproportionate to pathogen burden
Temporal relationship between immune recovery and symptom onset

Minor Criteria:

Elevated inflammatory markers (C-reactive protein, procalcitonin)
Lymphocyte count recovery
Radiological progression despite treatment
Response to anti-inflammatory therapy

Laboratory Investigations

Inflammatory Markers:

C-reactive protein (CRP): Often markedly elevated (>100 mg/L)
Procalcitonin: May be elevated but less specific
Erythrocyte sedimentation rate (ESR): Typically elevated
Lactate dehydrogenase (LDH): Often increased

Immunological Parameters:

Complete blood count with differential
Lymphocyte subsets (CD4+, CD8+ counts)
Immunoglobulin levels
Complement levels (C3, C4)

Microbiological Studies:

Blood cultures and sensitivity testing
Sputum or respiratory secretion analysis
Cerebrospinal fluid examination when indicated
Tissue biopsies for histopathological examination

Radiological Findings

Chest Imaging:

New or worsening pulmonary infiltrates
Mediastinal lymphadenopathy
Pleural effusions
Cavitary lesions

Abdominal Imaging:

Hepatosplenomegaly
Intra-abdominal lymphadenopathy
Bowel wall thickening

Neuroimaging:

Cerebral edema
Ring-enhancing lesions
Hydrocephalus

Differential Diagnosis

IRIS must be differentiated from several conditions commonly encountered in ICU patients:

Treatment Failure: Inadequate antimicrobial therapy, drug resistance, or poor drug penetration Superinfection: New infections with different pathogens Drug Reactions: Allergic or adverse drug reactions Malignancy: Lymphomas or other malignancies Autoimmune Conditions: Systemic inflammatory diseases

Specific Clinical Scenarios

Post-Sepsis IRIS

Post-sepsis IRIS represents a unique challenge in critical care. As patients recover from severe sepsis, the restoration of immune function can trigger inflammatory responses against residual pathogens or previously controlled infections. This phenomenon is particularly common in patients who experienced prolonged ICU stays with multiple infectious complications.

Clinical Pearls:

Maintain high suspicion in patients with fever recurrence 1-4 weeks post-sepsis recovery
Consider IRIS when new infiltrates appear despite appropriate antimicrobial therapy
Monitor lymphocyte count recovery as a marker of immune reconstitution

Management Approach:

Continue appropriate antimicrobial therapy
Consider low-dose corticosteroids (prednisolone 0.5-1 mg/kg/day)
Avoid abrupt cessation of immunosuppressive agents

Steroid Withdrawal IRIS

Corticosteroid withdrawal is one of the most common triggers of IRIS in ICU patients. The syndrome typically occurs when steroids are rapidly tapered or discontinued, particularly in patients with underlying infections.

Risk Factors:

High-dose steroid therapy (>1 mg/kg prednisolone equivalent)
Prolonged steroid administration (>2 weeks)
Underlying chronic infections (tuberculosis, fungal infections)
Rapid tapering schedules

Clinical Pearls:

Implement gradual steroid tapering protocols
Screen for occult infections before steroid initiation
Monitor for signs of immune reconstitution during tapering

Steroid Tapering Principles:

Reduce by 25-50% weekly for doses >40 mg prednisolone equivalent
Reduce by 10-25% weekly for doses 20-40 mg prednisolone equivalent
Reduce by 5-10% weekly for doses <20 mg prednisolone equivalent
Extend tapering schedule if IRIS symptoms develop

Tuberculosis-Associated IRIS

Tuberculosis (TB) is one of the most common infections associated with IRIS in ICU patients, particularly in endemic areas. TB-IRIS can present as either unmasking or paradoxical forms.

Unmasking TB-IRIS:

New onset fever, cough, or weight loss
Pulmonary infiltrates on chest imaging
Positive tuberculin skin test or interferon-gamma release assays
Positive acid-fast bacilli on sputum examination

Paradoxical TB-IRIS:

Worsening symptoms despite appropriate anti-TB therapy
New or enlarging lymph nodes
Worsening radiological findings
Pleural effusions or pericardial involvement

Management Strategies:

Continue anti-TB therapy
Consider corticosteroids for severe cases (prednisolone 1-2 mg/kg/day)
Monitor for drug interactions between steroids and anti-TB medications
Gradual steroid tapering over 4-6 weeks

Cytomegalovirus (CMV) IRIS

CMV-IRIS is particularly relevant in immunocompromised ICU patients, including transplant recipients and patients receiving immunosuppressive therapy.

Clinical Manifestations:

Fever and constitutional symptoms
Retinitis or visual changes
Gastrointestinal symptoms (colitis, hepatitis)
Pneumonitis or respiratory symptoms

Diagnostic Approach:

CMV PCR quantification
Tissue biopsy for histopathological confirmation
Ophthalmological examination for retinitis

Management:

Continue or initiate anti-CMV therapy (ganciclovir, valganciclovir)
Consider corticosteroids for severe inflammatory responses
Monitor for drug toxicities and interactions

Fungal IRIS

Fungal infections, particularly those caused by Candida, Aspergillus, and endemic fungi, can precipitate IRIS in ICU patients.

Common Presentations:

Persistent fever despite antifungal therapy
Worsening pulmonary infiltrates
New skin lesions or lymphadenopathy
Hepatosplenic involvement

Management Considerations:

Confirm fungal etiology with appropriate diagnostic tests
Optimize antifungal therapy based on susceptibility testing
Consider corticosteroids for severe inflammatory responses
Monitor for antifungal drug interactions

Management Strategies

General Principles

Managing IRIS in ICU patients requires a multimodal approach that addresses both the inflammatory response and the underlying infection. The primary goals are to control excessive inflammation while maintaining effective antimicrobial therapy.

Core Management Principles:

Pathogen-Specific Therapy: Continue appropriate antimicrobial therapy based on identified pathogens
Anti-Inflammatory Control: Use corticosteroids or other anti-inflammatory agents judiciously
Supportive Care: Maintain organ function and prevent complications
Monitoring: Close surveillance for treatment response and adverse effects

Anti-Inflammatory Management

Corticosteroids: Corticosteroids remain the cornerstone of IRIS management, but their use requires careful consideration of risks and benefits.

Indications for Corticosteroids:

Severe respiratory distress or organ dysfunction
Life-threatening inflammation
Failure to respond to antimicrobial therapy alone
Neurological involvement with cerebral edema

Dosing Strategies:

Mild IRIS: Prednisolone 0.5-1 mg/kg/day
Moderate IRIS: Prednisolone 1-2 mg/kg/day
Severe IRIS: Methylprednisolone 1-2 mg/kg/day IV or prednisolone 2-4 mg/kg/day
Neurological IRIS: High-dose corticosteroids (methylprednisolone 10-15 mg/kg/day)

Tapering Protocols:

Initial treatment duration: 2-4 weeks
Gradual tapering over 4-12 weeks depending on severity
Monitor for symptom recurrence during tapering
Adjust tapering schedule based on clinical response

Alternative Anti-Inflammatory Agents: When corticosteroids are contraindicated or ineffective, alternative agents may be considered:

Non-steroidal anti-inflammatory drugs (NSAIDs): Limited use due to renal and gastrointestinal toxicity
Tumor necrosis factor inhibitors: Infliximab or adalimumab for refractory cases
Interleukin-6 receptor antagonists: Tocilizumab for severe inflammatory responses
Thalidomide: Anti-TNF properties, useful in specific cases

Antimicrobial Management

Pathogen-Directed Therapy:

Continue appropriate antimicrobial therapy based on culture results
Optimize dosing based on pharmacokinetic/pharmacodynamic principles
Monitor for drug interactions with anti-inflammatory agents
Adjust therapy based on clinical response

Duration of Therapy:

Extend antimicrobial therapy duration in IRIS patients
Consider longer courses for complex infections
Monitor for treatment failure or resistance development

Supportive Care

Respiratory Support:

Mechanical ventilation for acute respiratory failure
Non-invasive ventilation for mild to moderate respiratory distress
Bronchoscopy for diagnostic sampling and therapeutic intervention
Chest physiotherapy and pulmonary rehabilitation

Hemodynamic Support:

Fluid resuscitation for hypotension or shock
Vasopressor therapy for distributive shock
Inotropic support for cardiogenic shock
Hemodynamic monitoring with appropriate devices

Nutritional Support:

Early enteral nutrition when possible
Parenteral nutrition for patients with gastrointestinal contraindications
Micronutrient supplementation
Protein requirements: 1.2-2.0 g/kg/day

Renal Support:

Continuous renal replacement therapy for acute kidney injury
Electrolyte and acid-base management
Fluid balance optimization

Monitoring and Follow-up

Clinical Monitoring

Vital Signs and Clinical Parameters:

Temperature patterns and fever response
Respiratory rate and oxygen saturation
Blood pressure and heart rate
Neurological status and Glasgow Coma Scale
Urine output and fluid balance

Laboratory Monitoring:

Daily complete blood count with differential
Comprehensive metabolic panel
Inflammatory markers (CRP, ESR, procalcitonin)
Liver function tests
Coagulation studies

Microbiological Surveillance:

Regular blood cultures
Respiratory secretion analysis
Urine cultures
Wound cultures when applicable

Radiological Monitoring

Chest Imaging:

Daily chest X-rays for mechanically ventilated patients
Chest CT for complex pulmonary cases
Serial imaging to assess treatment response

Abdominal Imaging:

Ultrasound for hepatosplenic involvement
CT scan for intra-abdominal complications
MRCP for biliary complications

Response Assessment

Clinical Response Criteria:

Fever resolution or improvement
Improvement in respiratory symptoms
Normalization of inflammatory markers
Resolution of organ dysfunction

Radiological Response:

Improvement in pulmonary infiltrates
Resolution of lymphadenopathy
Decrease in pleural effusions

Laboratory Response:

Decreasing inflammatory markers
Normalization of white blood cell count
Improvement in organ function tests

Complications and Adverse Events

IRIS-Related Complications

Respiratory Complications:

Acute respiratory distress syndrome (ARDS)
Respiratory failure requiring prolonged mechanical ventilation
Pneumothorax or pneumomediastinum
Pulmonary embolism

Cardiovascular Complications:

Distributive shock
Cardiogenic shock
Arrhythmias
Pericarditis or pericardial effusion

Neurological Complications:

Cerebral edema and increased intracranial pressure
Seizures
Stroke or intracranial hemorrhage
Peripheral neuropathy

Renal Complications:

Acute kidney injury
Electrolyte imbalances
Fluid overload

Treatment-Related Adverse Events

Corticosteroid-Related Complications:

Hyperglycemia and diabetes mellitus
Hypertension
Osteoporosis and fractures
Gastrointestinal bleeding
Opportunistic infections
Psychiatric disturbances

Antimicrobial-Related Complications:

Drug resistance development
Clostridioides difficile infection
Hepatotoxicity
Nephrotoxicity
Allergic reactions

Prevention Strategies

Risk Stratification:

Identify high-risk patients for IRIS development
Implement screening protocols for occult infections
Optimize immune status before planned procedures

Prophylactic Measures:

Gradual steroid tapering protocols
Antimicrobial prophylaxis in high-risk patients
Nutritional optimization
Vaccination when appropriate

Clinical Pearls and Oysters

Pearls for Clinical Practice

Pearl 1: Timing is Everything IRIS typically occurs 1-4 weeks after immune recovery begins. Maintain high suspicion during this critical window, especially in patients with recent steroid withdrawal or sepsis recovery.

Pearl 2: The Fever Paradox Fever in IRIS patients doesn't always indicate treatment failure. Consider IRIS when patients develop new fever despite appropriate antimicrobial therapy and clinical improvement.

Pearl 3: Steroid Tapering Strategy Implement a "rule of halves" for steroid tapering: reduce by 50% weekly for high doses, 25% weekly for moderate doses, and 10% weekly for low doses.

Pearl 4: Laboratory Clues Watch for lymphocyte count recovery (>500-1000 cells/μL) as an early indicator of immune reconstitution. This often precedes clinical IRIS by 1-2 weeks.

Pearl 5: Radiological Progression Worsening radiological findings despite clinical improvement can be an early sign of IRIS. Don't be fooled by improving clinical parameters if imaging shows progression.

Oysters (Common Pitfalls)

Oyster 1: Mistaking IRIS for Treatment Failure The most common mistake is interpreting IRIS as antimicrobial treatment failure, leading to unnecessary antibiotic escalation or changes. Always consider IRIS in the differential diagnosis of clinical deterioration.

Oyster 2: Steroid Phobia Fear of using corticosteroids in infected patients can delay appropriate IRIS treatment. When IRIS is suspected, judicious steroid use can be life-saving.

Oyster 3: Over-Reliance on Procalcitonin Procalcitonin can be elevated in IRIS due to inflammatory response, not necessarily bacterial infection. Use it cautiously and in conjunction with clinical assessment.

Oyster 4: Ignoring the Immune Recovery Timeline Failing to recognize the temporal relationship between immune recovery and symptom onset can lead to misdiagnosis. Always consider recent changes in immune status.

Oyster 5: Premature Steroid Withdrawal Tapering steroids too quickly in IRIS patients can lead to symptom recurrence. Patience is key in steroid withdrawal protocols.

ICU Hacks and Practical Tips

Hack 1: The "IRIS Clock" Create a mental timeline for each patient: immune suppression → recovery trigger → expected IRIS window (1-4 weeks). This helps in early recognition.

Hack 2: Inflammatory Marker Trending Use CRP and ESR trends rather than absolute values. Sudden increases during apparent recovery should raise IRIS suspicion.

Hack 3: The Steroid Bridge When discontinuing other immunosuppressive agents, consider a short course of corticosteroids as a "bridge" to prevent IRIS.

Hack 4: Multidisciplinary Approach Establish early collaboration with infectious disease specialists, rheumatologists, and pulmonologists. IRIS management benefits from multidisciplinary expertise.

Hack 5: Patient Education Educate patients and families about IRIS possibility during recovery. This helps in early recognition and reduces anxiety when symptoms occur.

Future Directions and Research

Emerging Biomarkers

Research is ongoing to identify specific biomarkers that can predict IRIS development and monitor treatment response. Promising candidates include:

Cytokine Profiles: IL-6, TNF-α, IFN-γ patterns
Immune Cell Markers: T-cell activation markers, regulatory T-cell counts
Genetic Markers: Polymorphisms in cytokine genes
Metabolomic Signatures: Metabolic profiles associated with IRIS

Novel Therapeutic Approaches

Targeted Immunotherapy:

Monoclonal antibodies against specific cytokines
Small molecule inhibitors of inflammatory pathways
Adoptive cell therapy approaches

Precision Medicine:

Personalized treatment based on genetic profiles
Biomarker-guided therapy selection
Individualized steroid tapering protocols

Diagnostic Innovations

Point-of-Care Testing:

Rapid cytokine measurement devices
Portable inflammatory marker analyzers
Real-time immune status monitoring

Artificial Intelligence:

Machine learning algorithms for IRIS prediction
Pattern recognition in clinical data
Automated clinical decision support systems

Conclusion

Immune Reconstitution Inflammatory Syndrome represents a significant challenge in contemporary critical care practice. As our understanding of immune dysfunction in critical illness evolves, recognition of IRIS becomes increasingly important for optimal patient outcomes. The syndrome's paradoxical nature—clinical deterioration during apparent recovery—makes it particularly challenging to diagnose and manage.

Key takeaways for critical care practitioners include maintaining high clinical suspicion during immune recovery phases, implementing systematic diagnostic approaches, and utilizing evidence-based management strategies that balance anti-inflammatory therapy with infection control. The judicious use of corticosteroids, when appropriately indicated, can be life-saving in severe IRIS cases.

The complexity of IRIS in ICU patients necessitates a multidisciplinary approach, incorporating expertise from critical care, infectious diseases, and immunology. As research continues to uncover new biomarkers and therapeutic targets, the future of IRIS management looks promising, with the potential for more personalized and effective treatment strategies.

Critical care physicians must remain vigilant for IRIS in their practice, particularly in patients recovering from sepsis, undergoing steroid withdrawal, or experiencing immune reconstitution. Early recognition and appropriate management can significantly improve outcomes and reduce the morbidity associated with this challenging syndrome.

References

Müller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(4):251-261.
Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005;19(4):399-406.
Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487-2498.
Lai RP, Meintjes G, Wilkinson RJ. HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome. Semin Immunopathol. 2016;38(2):185-198.
Haddow LJ, Easterbrook PJ, Mosam A, et al. Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort. Clin Infect Dis. 2009;49(9):1424-1432.
Robertson J, Meier M, Wall J, et al. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis. 2006;42(11):1639-1646.
Murdoch DM, Venter WD, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther. 2007;4:9.
Tan DB, Yong YK, Tan HY, et al. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Med. 2008;9(5):307-316.
Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis. 2004;39(11):1709-1712.
Achenbach CJ, Harrington RD, Dhanireddy S, et al. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis. 2012;54(3):424-433.
Müller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(4):251-261.
French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 2000;1(2):107-115.
Cheng VC, Yuen KY, Chan WM, et al. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis. 2000;30(6):882-892.
Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE. 2009;4(5):e5575.
Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8(8):516-523.
Török ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis. 2011;52(11):1374-1383.
Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365(16):1492-1501.
Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365(16):1471-1481.
Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365(16):1482-1491.
Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010;24(15):2381-2390.

Sunday, June 29, 2025